SHL.DE stock trades at €42.15 after hours on XETRA as Siemens Healthineers prepares to report results on 05 Feb 2026. Investors are watching revenue mix across Imaging, Diagnostics, Varian and Advanced Therapies ahead of the print. The share price sits below the 50‑day average of €44.20 and well under the year high of €58.48, while market participants monitor volumes of 1,205,531 and a market cap near €47.27 billion.
Earnings catalyst for SHL.DE stock
SHL.DE stock faces a clear catalyst: the earnings release scheduled for 05 Feb 2026 that will include results and guidance from Imaging and Varian. Analysts expect the report to clarify order trends and margin direction, which could drive intraday volatility on XETRA.
Valuation and financials for SHL.DE stock
Siemens Healthineers trades at PE 22.07 with EPS €1.91, below the German healthcare sector average PE of 33.39. The company shows a strong free cash flow per share of €2.03 and dividend per share of €0.95, yielding about 2.25%.
Technical picture and trading data for SHL.DE stock
Price momentum is firm but stretched: RSI at 69.29 and MACD histogram 0.28 suggest near-term strength. The stock trades below the 200‑day average of €46.18, with daily range €42.01–€43.15 and relative volume 1.26.
Meyka grade and forecast for SHL.DE stock
Meyka AI rates SHL.DE with a score of 69.34 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €47.33 versus the current €42.15.
Risks and opportunities for SHL.DE stock
Key risks are slower Diagnostics demand and integration execution at Varian, with net debt to EBITDA at 2.81 raising refinancing sensitivity. Opportunities include margin recovery in Imaging, recurring services revenue, and digital solutions that could lift valuation toward peers.
Market context and analyst signals for SHL.DE stock
Recent sentiment is neutral: company rating shows B / Neutral with mixed metric scores, and daily volume is above average at 1,205,531 shares. Compare coverage and news at MarketBeat and regional trading data at Reuters.
Final Thoughts
Key takeaways for SHL.DE stock ahead of the Feb 05 earnings are simple. The share trades at €42.15 after hours on XETRA with a market cap near €47.27 billion and EPS of €1.91. Valuation metrics show a reasonable PE of 22.07 versus the healthcare sector average of 33.39, leaving room for multiple expansion if growth and margins improve. Meyka AI’s forecast model projects €47.33 at the one‑year horizon, implying an upside of 12.29% versus the current price. Our Meyka grade is B (69.34) with a HOLD suggestion; this balances solid cash flow and dividend yield of 2.25% against leverage and execution risks. Earnings on 05 Feb 2026 are the immediate driver. Traders should watch guidance, order intake commentary, and service revenue trends to decide on repositioning. For the live quote and model details visit the Meyka SHL.DE page. Meyka AI is an AI-powered market analysis platform providing data-driven outlooks. Forecasts are model-based projections and not guarantees.
FAQs
When does Siemens Healthineers report earnings and how will that affect SHL.DE stock?
Earnings are scheduled for 05 Feb 2026. The report could move SHL.DE stock sharply if management revises guidance, shows margin improvement, or details order trends in Imaging and Varian.
What valuation metrics matter for SHL.DE stock now?
Key metrics: PE 22.07, EPS €1.91, price to sales 2.02, and free cash flow per share €2.03. Compare these to the sector PE of 33.39 for context.
What is Meyka AI’s stance on SHL.DE stock?
Meyka AI rates SHL.DE 69.34/100 (B) – HOLD. The grade weighs benchmark and sector comparison, growth, key metrics, forecasts, and consensus. Grades are not guaranteed and are not financial advice.
What upside does Meyka AI forecast for SHL.DE stock?
Meyka AI’s forecast model projects €47.33 one year out, implying about 12.29% upside from the after‑hours price of €42.15. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)